Their state of the art manufacturing facilities feature the most advanced

Their state of the art manufacturing facilities

This preview shows page 30 - 33 out of 38 pages.

Their state-of-the-art manufacturing facilities feature the most advanced testing equipment to guarantee the quality of our products. Equipment is tested and certified, and every manufacturing process is validated. All supplier procedures are strictly supervised to ensure that only the highest grade materials are used in our products. Teva’s impeccable adherence to Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) is recognized by FDA approval of 26 of their plants, and EMA approval of 31 of their plants. Moreover, each of our pharmaceutical manufacturing facilities is inspected and approved by at least two regulatory authorities worldwide. They never rest on our laurels, and their passion for excellence drives them to continually improve practices so that processes and procedures are continuously updated. With a global presence, timely, reliable and cost-effective distribution is critical to their customers’ ability to provide their end consumers with safe and effective products at the right time. Their manufacturing network is continuously optimized so that their customers can have full confidence in our supply chain. This is enabled by high-volume, technologically-advanced distribution facilities. These facilities allow them to deliver new products swiftly and reliably. They continually review our capabilities and capacity. This ensures that they can consistently deliver best-in-class products. Their customers know that their end-consumers are receiving high-quality healthcare and wellness pharmaceuticals. The core and success of their continuous drive for excellence is expressed in the values of their global team. Their commitment and sense of responsibility are derived from the awareness that every product that they make will affect another person’s health. And health is the cornerstone of their dedication to making life better TOWS Analysis THREATS 30
Image of page 30
1. Stringent marketing and manufacturing regulations 2. Disruption in the global supply chain due economic changes 3. More resourceful companies entering Generics market OPPORTUNITIES 1. Increasing generic market WEAKNESSES 1. A drop in the sale of major anesthetic drugs 2. Since the company gets most of its revenue from outside U.S., it is vulnerable to macro -economic fluctuations STRENGTHS Worldwide presence, in over 60 countries with more than 46000 well trained employees No. 1 GENERIC company in the world Over 1300 molecules Patent for Copaxone (world’s largest selling multiple sclerosis drug INNOVATION Future of the Company 31
Image of page 31
Teva is interested in a broad array of approaches: Small molecule drugs Biologic opportunities (peptides, proteins, antibodies, nucleic acids, etc.) Biosimilar opportunities Reformulation or delivery opportunities that offer clinically meaningful benefits and potential for expedited regulatory review New drug modalities including long-acting RNA interference drugs, vaccines against self-antigens, CRISPR therapeutics and small molecules that control ribosomal activity
Image of page 32
Image of page 33

You've reached the end of your free preview.

Want to read all 38 pages?

  • Spring '18
  • DR.PRASAD

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture